James Revkin

Dr. James Revkin is an Associate Clinical Professor at the Yale School of Medicine (Yale University), specializing in the primary and secondary prevention of cardiovascular disease. He is an expert in the design and conduct of clinical trials for cardiovascular and metabolic diseases, particularly focusing on atherosclerosis, hypertension, heart failure, obesity, and diabetes. His work emphasizes the use of vascular imaging biomarkers to evaluate pharmaceutical agents' efficacy in slowing atherosclerosis progression.

Education & Training:

• MD, Brown University (1981)
• BA in Philosophy/French, Williams College (1976)
• Residency: Columbia-Presbyterian Medical Center (1984)
• Fellowship: Yale University School of Medicine (1987)
• Postdoctoral Trainee: Center for Bioengineering, University of Washington (1988)

Research Interests:

Dr. Revkin’s research focuses on clinical trial design for cardiovascular and metabolic diseases, with a particular emphasis on:

• Cardiovascular outcomes in patients with heart failure and cachexia
• Pharmacological interventions targeting growth differentiation factor-15 (GDF-15) in cancer cachexia
• Screening strategies for atrial fibrillation using wearable ECG monitors
• PCSK9 inhibitors and their role in familial hypercholesterolemia

Advising & Grants:

As a subject matter expert, Dr. Revkin collaborates on industry-sponsored trials and leads teams in:

• Phase 1b–2 clinical trials for drugs like ponsegromab
• Systematic reviews and meta-analyses of cancer cachexia outcomes
• Rationale-driven trial design for cardiovascular risk reduction (e.g., GUARD-AF study)

Labs/Teams:

His work is integrated into Yale’s cardiovascular research programs, focusing on translational studies and collaborative teams such as the:

• Studies of PCSK9 Inhibition and the Reduction of Vascular Events (SPIRE)
• PROACC-1 trial for cancer cachexia